Publications 2005

 

Levy Y, Gahery-Segard H, Durier C, Lascaux A.S., Goujard C, Meiffrédy V, Rouzioux C, Habib R, Beumont-Mauviel M, Guillet JG, Delfraissy JF, Aboulker JP, and the ANRS 093 Study Group. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005, 19:279-86.Lien PubMed

Morand-Joubert L, Marcellin F, Launay O, Guiramand-Hugon S, Gerard L, Yeni P, Aboulker JP, for the Agence Nationale de Recherches sur le SIDA 081 Study Group.Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomised comparison of 2 regimens, including 3 drugs from 2 or 3 classes.
J Acquir Immune Defic Syndr 2005, 38:268-76. Lien PubMed

Descamps D, Joly V, Flandre P, Peytavin G, Meiffrédy V, Delarue S, Lastère S, Aboulker JP, Yeni P, Brun-Vézinet F.Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial : (Novavir ANRS 073).
J Clin Virol 2005, 33:99-103. Lien PubMed

Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentré F, Peytavin G, Gérard L, Becquemont L, Aboulker JP, for the ANRS 081 Study Group. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS 2005, 19 :2127-31.
Lien PubMed

Hoen B, Fournier I, Lacabaratz C, Burgard M, Charreau I, Chaix ML, Molina JM, Livrozet JM, Venet A, Raffi F, Aboulker JP, Rouzioux C for the Primstop study group.Structured Treatment Interruptions in Primary HIV-1 Infection: the ANRS 100 PRIMSTOP Trial
J AIDS 2005, 40:307-16.Lien PubMed

Dunn DT, Gibb DM, Duong T, Babiker AG, Aboulker JP, Bulterys M, Cortina-Borja M, Gabiano C, Galli L, Giaquinto C, Harris DR, Hughes M, McKinney R, Moye J, Newell ML, Pahwa S, Palumbo P, Rudin C, Sharland M, Shearer W, Thompson B, Tookey P.Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data.
Lancet 2005, 366:1868-74.Lien PubMed

Payen S, Faye A, Compagnucci A, Giaquinto C, Gibbs D, Gomeni R, Bressolle F, Jacqz-Aigrain E.Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Antimicr Ag Chem 2005, 49:525-35.Lien PubMed